多西他赛对比奥沙利铂联合卡培他滨治疗晚期胃癌的临床
观察
郑波;刘君;金莉
【期刊名称】《中国继续医学教育》 【年(卷),期】2015(000)004
【摘要】Objective To explore the clinical effect and adverse reaction of taxotere (TXT) combined with xeloda versus oxaliplatin (LOHP) combined with xeloda in the treatment of advanced gastric cancer. Methods 49 cases of patients with advanced gastric cancer were randomly selected and divided into two groups. A group (n=24) received TXT combined with xeloda treatment, and B group (n=25) received LOHP combined with
xeloda treatment. Results The effective rate (CR+PR) in two groups were 54.17% and 56%, the progression free survival (PFS) were 6.1 months (95%CI: 5.36~9.84) and 6.3 months (95%CI: 5.12~9.46), there was no signiifcant difference (P>0.05). Conclusion The effect of TXT and LOHP combined with xeloda in the treatment of advanced gastric cancer is equivalent, and the adverse reactions is tolerable.%目的：探讨多西他赛（TXT）联合卡培他滨（希罗达，Xeloda）对比奥沙利铂（LOHP）联合希罗达（Xeloda）治疗晚期胃癌的临床疗效和不良反应。方法选取我院收治的49例晚期胃癌患者，随机分为两组。A组24例患者采用TXT联合Xeloda治疗方案。B组25例采用LOHP联合Xeloda治疗方案。结果A，B两组有效率、中位无进展生存期分别
多西他赛对比奥沙利铂联合卡培他滨治疗晚期胃癌的临床观察
